In this issue:
mCRC
Trifluridine/tipiracil survival benefit in Asian patients
Survival benefit with maintenance therapy vs observation
Potential for surgical resection of metastases
Plasma vs tissue testing of RAS mutation
Bevacizumab + chemotherapy in elderly patients
Genomic alterations and anti-EGFR therapy selection
Rectal cancer
Sorafenib + neoadjuvant chemoradiotherapy
Biomarkers associated with worse survival
Improved OS with adjuvant chemotherapy
Long-term care and durable disease control
Please login below to download this issue (PDF)